At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09995 REMEGEN
Not Yet Opened 08-12 16:08:08
82.300
-1.400
-1.67%
High85.250Low81.850Vol2.14M
Open83.900D1 Closing83.700Amplitude4.06%
Mkt Cap46.38BTradable Cap17.17BTotal Shares563.61M
T/O176.99MT/O Rate1.02%Tradable Shares208.58M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Stock Track | REMEGEN Soars 5.10% Intraday on H1 Profit Turnaround and AbbVie Licensing Deal
Stock Track  ·  08-10 09:48
Stock Track | REMEGEN Soars 5.10% Intraday on H1 Profit Turnaround and AbbVie Licensing Deal
Movement Alert｜REMEGEN Rises 3.88% in Regular Trading, H1 Earnings Preview Shows Turnaround to Profitability with 47 Billion Yuan Net Profit
Market Focus  ·  08-10 09:46
Movement Alert｜REMEGEN Rises 3.88% in Regular Trading, H1 Earnings Preview Shows Turnaround to Profitability with 47 Billion Yuan Net Profit
Hong Kong Stocks in Focus: Remegen Surges Over 5% Before Noon, Achieves First Major Mid-Term Profit Driven by Overseas Licensing
Stock News  ·  08-07
Hong Kong Stocks in Focus: Remegen Surges Over 5% Before Noon, Achieves First Major Mid-Term Profit Driven by Overseas Licensing
Movement Alert｜REMEGEN Rises 5.03% in Regular Trading, H1 Earnings Swing to Profit with Essential Drug Catalog Catalyst
Market Focus  ·  08-07
Movement Alert｜REMEGEN Rises 5.03% in Regular Trading, H1 Earnings Swing to Profit with Essential Drug Catalog Catalyst
RemeGen Expects to Return to Profit in H1; Hong Kong Shares Down 3%
MT Newswires Live  ·  08-06
RemeGen Expects to Return to Profit in H1; Hong Kong Shares Down 3%
Hong Kong Stock Moves: Remegen Opens Nearly 4% Higher, Anticipates First-Half Net Profit Attributable to Parent of Approximately 4.7 Billion Yuan
Stock News  ·  08-06
Hong Kong Stock Moves: Remegen Opens Nearly 4% Higher, Anticipates First-Half Net Profit Attributable to Parent of Approximately 4.7 Billion Yuan
RemeGen forecasts 1H26 net profit of RMB4.70 billion on 433% revenue surge
Bulletin Express  ·  08-05
RemeGen forecasts 1H26 net profit of RMB4.70 billion on 433% revenue surge
RemeGen’s July 2026 Share Update: H-Share Base Steady, A-Share Buyback Trims Free Float by 13,000 Shares
Bulletin Express  ·  08-04
RemeGen’s July 2026 Share Update: H-Share Base Steady, A-Share Buyback Trims Free Float by 13,000 Shares
Remegen Spends Approximately 3.05 Million Yuan to Buy Back 28,000 Shares on August 3
Stock News  ·  08-03
Remegen Spends Approximately 3.05 Million Yuan to Buy Back 28,000 Shares on August 3
Hong Kong Stock Movers: Several Innovative Drug Stocks Rally in Afternoon Trading, GENSCRIPT BIO Surges Nearly 8%, REMEGEN Gains Over 4%
Stock News  ·  07-31
Hong Kong Stock Movers: Several Innovative Drug Stocks Rally in Afternoon Trading, GENSCRIPT BIO Surges Nearly 8%, REMEGEN Gains Over 4%
RemeGen repurchases 13,000 A-shares for RMB1.43 million, outstanding share count falls 0.0037%
Bulletin Express  ·  07-30
RemeGen repurchases 13,000 A-shares for RMB1.43 million, outstanding share count falls 0.0037%
Movement Alert｜REMEGEN Intraday Decline 5.02%, Ophthalmic Drug RC28-E Registration Apparently Rejected by NMPA
Market Focus  ·  07-30
Movement Alert｜REMEGEN Intraday Decline 5.02%, Ophthalmic Drug RC28-E Registration Apparently Rejected by NMPA
Nomura Adjusts RemeGen's Price Target to HK$89.44 From HK$79.64, Keeps at Neutral
MT Newswires Live  ·  07-27
Nomura Adjusts RemeGen's Price Target to HK$89.44 From HK$79.64, Keeps at Neutral
Movement Alert｜REMEGEN Falls 5.1% in Regular Trading, Lock-Up Expiry Selling Pressure Compounded by Biotech Sector Pullback
Market Focus  ·  07-24
Movement Alert｜REMEGEN Falls 5.1% in Regular Trading, Lock-Up Expiry Selling Pressure Compounded by Biotech Sector Pullback
Movement Alert｜RemeGen Rises 4.23% in Regular Trading, A-Share Buyback Plan Enters Implementation Phase as Innovative Drug Sector Strengthens
Market Focus  ·  07-22
Movement Alert｜RemeGen Rises 4.23% in Regular Trading, A-Share Buyback Plan Enters Implementation Phase as Innovative Drug Sector Strengthens
Innovative Drug Stocks Rebound Swiftly, Leading ETF Surges as Sector Gains Momentum with Positive Developments from Multiple Companies
Deep News  ·  07-20
Innovative Drug Stocks Rebound Swiftly, Leading ETF Surges as Sector Gains Momentum with Positive Developments from Multiple Companies
REMEGEN Shares Surge Over 8% on Proposed A-Share Buyback and Positive Outlook for Telitacicept
Stock News  ·  07-20
REMEGEN Shares Surge Over 8% on Proposed A-Share Buyback and Positive Outlook for Telitacicept
RemeGen Proposes Share Buyback of Up to 50 Million Yuan
MT Newswires Live  ·  07-20
RemeGen Proposes Share Buyback of Up to 50 Million Yuan
HK Movers | Biomedical Stocks Rally; REMEGEN, WUXI XDC and KEYMED BIO-B Surge Over 8%
Tiger Newspress  ·  07-20
HK Movers | Biomedical Stocks Rally; REMEGEN, WUXI XDC and KEYMED BIO-B Surge Over 8%
Hong Kong Stock Connect Biotech Sector Stages Strong Rebound, Key ETF Surges Over 4%; REMEGEN Announces Buyback, Leading Gains
Deep News  ·  07-20
Hong Kong Stock Connect Biotech Sector Stages Strong Rebound, Key ETF Surges Over 4%; REMEGEN Announces Buyback, Leading Gains
No data available

Introduction

Company Name.
REMEGEN
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
RemeGen Co Ltd is a China-based company principally engaged in biopharmaceutical research, biopharmaceutical service, biopharmaceutical production and sale. The Company focuses on therapeutic antibody drugs such as antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company’s main products include telitacicept, disitamab vedotin, RC28-E and others. The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly operates its businesses in the domestic and overseas markets.
Issue price:
--